INHIBIKASE THERAPEUTICS INC (IKT) Stock Fundamental Analysis
NASDAQ:IKT - Nasdaq - US45719W2052 - Common Stock
Taking everything into account, IKT scores 1 out of 10 in our fundamental rating. IKT was compared to 572 industry peers in the Biotechnology industry. IKT may be in some trouble as it scores bad on both profitability and health. IKT has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year IKT has reported negative net income.
IKT had a negative operating cash flow in the past year.
IKT had negative earnings in each of the past 5 years.
In the past 5 years IKT always reported negative operating cash flow.
1.2 Ratios
IKT has a worse Return On Assets (-447.01%) than 97.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -447.01% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-79.46%
ROA(5y)-2911.53%
ROE(3y)-99.21%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for IKT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IKT does not have a ROIC to compare to the WACC, probably because it is not profitable.
IKT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, IKT has more shares outstanding
There is no outstanding debt for IKT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
IKT has an Altman-Z score of -18.56. This is a bad value and indicates that IKT is not financially healthy and even has some risk of bankruptcy.
IKT has a Altman-Z score of -18.56. This is amonst the worse of the industry: IKT underperforms 86.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -18.56 |
ROIC/WACCN/A
WACC11.11%
2.3 Liquidity
A Current Ratio of 0.85 indicates that IKT may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.85, IKT is doing worse than 90.44% of the companies in the same industry.
A Quick Ratio of 0.85 indicates that IKT may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.85, IKT is doing worse than 89.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.85 | ||
| Quick Ratio | 0.85 |
3. Growth
3.1 Past
IKT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.17%, which is quite impressive.
IKT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
The Revenue for IKT have been decreasing by -42.21% on average. This is quite bad
EPS 1Y (TTM)33.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.42%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-28.07%
Revenue growth 5Y-42.21%
Sales Q2Q%-100%
3.2 Future
Based on estimates for the next years, IKT will show a very strong growth in Earnings Per Share. The EPS will grow by 22.59% on average per year.
Based on estimates for the next years, IKT will show a very negative growth in Revenue. The Revenue will decrease by -25.99% on average per year.
EPS Next Y74.44%
EPS Next 2Y36.81%
EPS Next 3Y22.59%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
IKT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IKT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
IKT's earnings are expected to grow with 22.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.81%
EPS Next 3Y22.59%
5. Dividend
5.1 Amount
No dividends for IKT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INHIBIKASE THERAPEUTICS INC
NASDAQ:IKT (1/21/2025, 8:07:19 PM)
After market: 2.99 +0.18 (+6.41%)2.81
+0.09 (+3.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners22.72%
Inst Owner Change0%
Ins Owners12.02%
Ins Owner Change0.88%
Market Cap188.80M
Analysts82.86
Price Target7.14 (154.09%)
Short Float %1.63%
Short Ratio2.57
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-35.73%
Min EPS beat(2)-73.94%
Max EPS beat(2)2.47%
EPS beat(4)3
Avg EPS beat(4)-9.38%
Min EPS beat(4)-73.94%
Max EPS beat(4)25.45%
EPS beat(8)5
Avg EPS beat(8)-4.51%
EPS beat(12)7
Avg EPS beat(12)-4.18%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-39.13%
EPS NQ rev (1m)0%
EPS NQ rev (3m)75.93%
EPS NY rev (1m)0%
EPS NY rev (3m)64.44%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.68
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS0
BVpS-0.01
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -447.01% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-79.46%
ROA(5y)-2911.53%
ROE(3y)-99.21%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 15.64% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.85 | ||
| Quick Ratio | 0.85 | ||
| Altman-Z | -18.56 |
F-Score2
WACC11.11%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.42%
EPS Next Y74.44%
EPS Next 2Y36.81%
EPS Next 3Y22.59%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3Y-28.07%
Revenue growth 5Y-42.21%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y-0.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y4.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.59%
OCF growth 3YN/A
OCF growth 5YN/A